DHR vs PFE: Which Is the Better Buy?

Side-by-side comparison of Danaher Corporation and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-07-10.

DHR

Danaher Corporation · Healthcare

$195.98

+7.9% upside to fair value

Grade B High Quality

PFE

Pfizer Inc. · Healthcare

$25.22

+2.8% upside to fair value

Grade B

QuantHub Verdict

DHR has more upside to fair value (+7.9%). PFE trades at a lower forward P/E (19.2x). These are model outputs — not personalized investment advice. See all research →

Valuation & Fundamentals

Metric	DHR	PFE
Current Price	$195.98	$25.22
Fair Value Estimate	$211.54	$25.92
Upside to Fair Value	+7.9%	+2.8%
Market Cap	$138.7B	$143.7B
Forward P/E	37.8x	19.2x
EV / EBITDA	22.8x	12.3x
Price / Sales	5.6x	2.3x
Price / FCF	26.2x	15.2x
Revenue Growth YoY	+3.7%	+5.4%
Gross Margin	60.7%	69.3%
Operating Margin	21.0%	23.4%
Return on Equity	7.1%	8.4%
Dividend Yield	0%	0%
FCF Yield	3.81%	6.6%
Analyst Consensus	Strong Buy	Hold

Investment Thesis

DHR — Danaher Corporation

Danaher Corporation operates in the healthcare sector, specifically in medical diagnostics and research, delivering high-quality products with a durable competitive moat supported by strong margins and consistent earnings growth. The company trades at a trailing and forward P/E of 37.76, which is relatively high but justified by its stable revenue growth of 3.7% and earnings growth of 7.9% in the…

PFE — Pfizer Inc.

Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…

Accumulation Zones

Metric	DHR	PFE
Zone Low	$158.66	$19.44
Zone High	$179.81	$22.03
In Buy Zone?	No	No

← DHR Research PFE Research → All Research